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Background: Neuroinflammation is a common immune response associated with brain human immunodeficiency
virus-1 (HIV-1) infection. Identifying therapeutic compounds that exhibit better brain permeability and can target
signaling pathways involved in inflammation may benefit treatment of HIV-associated neurological complications.
The objective of this study was to implement an in vivo model of brain inflammation by intracerebroventricular
administration of the HIV-1 viral coat protein gp120 in rats and to examine anti-inflammatory properties of HIV
adjuvant therapies such as minocycline, chloroquine and simvastatin.
Methods: Male Wistar rats were administered a single dose of gp120ADA (500 ng) daily for seven consecutive days,
intracerebroventricularly, with or without prior intraperitoneal administration of minocycline, chloroquine or
simvastatin. Maraviroc, a CCR5 antagonist, was administered intracerebroventricularly prior to gp120 administration
for seven days as control. Real-time qPCR was used to assess gene expression of inflammatory markers in the frontal
cortex, hippocampus and striatum. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) secretion in cerebrospinal
fluid (CSF) was measured applying ELISA. Protein expression of mitogen-activated protein kinases (MAPKs) (extracellular
signal-related kinase 1/2 (ERK1/2), c-Jun N-terminal kinases (JNKs) and P38 kinases (P38Ks)) was detected using
immunoblot analysis. Student’s t-test and ANOVA were applied to determine statistical significance.
Results: In gp120ADA-injected rats, mRNA transcripts of interleukin-1β (IL-1β) and inducible nitric oxide synthase (iNOS)
were significantly elevated in the frontal cortex, striatum and hippocampus compared to saline or heat-inactivated
gp120-injected controls. In CSF, a significant increase in TNF-α and IL-1β was detected. Maraviroc reduced upregulation
of these markers suggesting that the interaction of R5-tropic gp120 to CCR5 chemokine receptor is critical for induction
of an inflammatory response. Minocycline, chloroquine or simvastatin attenuated upregulation of IL-1β and iNOS
transcripts in different brain regions. In CSF, minocycline suppressed TNF-α and IL-1β secretion, whereas chloroquine
attenuated IL-1β secretion. In gp120-injected animals, activation of ERK1/2 and JNKs was observed in the hippocampus
and ERK1/2 activation was significantly reduced by the anti-inflammatory agents.
Conclusions: Our data demonstrate that anti-inflammatory compounds can completely or partially reverse gp120-
associated brain inflammation through an interaction with MAPK signaling pathways and suggest their potential role in
contributing towards the prevention and treatment of HIV-associated neurological complications.
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Neurocognitive impairment remains highly prevalent in
human immunodeficiency virus-1 (HIV-1) infected indi-
viduals due to persistence of viral replication and associ-
ated inflammation in the brain [1]. Since the initiation of
highly active antiretroviral therapy (HAART), the de-
velopment of HIV-associated dementia (HAD) in HIV-1
infected patients has significantly decreased. However,
milder forms of HIV-associated neurocognitive disorders
(HAND) are becoming more predominant in the post-
HAART era, in part due to the longer life expectancy
of infected individuals on treatment. Despite receiving
treatment, up to 50% of HIV-1 infected patients con-
tinue to develop cognitive impairment, psychiatric illness
and persistent fatigue [1].
In response to HIV-1, resident microglia in the brain be-
come activated and release inflammatory mediators that
further trigger the activation of neighboring microglia and
astrocytes and signal recruitment of peripheral monocytes
from the systemic circulation [2]. Studies have demon-
strated that virus-infected cells or glial cells can release
various neurotoxic factors (arachidonic acid, platelet acti-
vating factor, quinolinic acid, reactive oxygen species, nitric
oxide, and glutamate) and a number of pro-inflammatory
cytokines (tumor necrosis factor-α (TNF-α), interleukin-1β
(IL-1β), IL-6, IL-8, IL-18, interferon α (IFNα), IFNγ) [2-4].
Irreversible neuronal injury and loss is often caused by
inflammation and oxidative stress associated with these
mediators present in the systemic circulation that crosses
the blood–brain barrier and/or mediators secreted in
the brain from glial cells. Detectable amounts of these
cytokines in the cerebrospinal fluid (CSF) of patients
with HIV-associated neurocognitive disorder have been
reported [4]. In vitro studies in primary glial cell cultures
also suggest that shed viral proteins (such as glyco-
protein120 (gp120), transactivator of transcription (tat),
and viral protein R (vpr)) can induce secretion of pro-
inflammatory cytokines. For example, previous work
from our laboratory has demonstrated that R5-tropic
gp120 can mediate secretion of pro-inflammatory cytokines
(TNF-α, IL-1β and IL-6) by interacting with CCR5 chemo-
kine receptor in primary cultures of human or rodent
astrocytes [5,6]. HIV-1 proteins (such as gp120 and tat)
can also downregulate tight junction proteins expressed
in brain microvessel endothelial cells which may facilitate
the entry of the virus into the brain parenchyma [7].
The treatment of brain HIV-1 infection remains challen-
ging partly due to poor permeability of antiretroviral drugs
across the blood-brain barrier and into glial cells. One
possible mechanism for the low brain permeability of
these drugs is the functional expression of ATP-dependent,
membrane-associated efflux transporters known as ATP-
binding cassette (ABC) transporters (P-glycoprotein (P-gp);
multidrug resistance proteins (MRPs) and breast cancerresistance protein (Bcrp)) at the blood-brain barrier and in
brain parenchyma [8]. Several in vivo and in vitro studies
have examined the role of these transporters in reducing
the permeability of antiretroviral drugs into brain cellular
compartments [8,9]. For example, administration of P-gp
specific inhibitor zosuquidar in macaques resulted in sig-
nificant brain accumulation of nelfinavir [9]. Evidence in
the literature suggests that functional expression of these
transporters in the brain is altered during HIV-1 infection.
Langford et al. reported increased P-gp immunoreactivity
in glial cells in brain autopsy tissues from patients with
HIV-encephalitis (HIVE), [10] whereas, Persidsky et al. re-
ported a decreased P-gp expression in tissues obtained
from HIVE patients and from the severe combined im-
munodeficiency (SCID) mice model of HIVE [11]. Further-
more, shed viral proteins (such as gp120 and Tat) and
secreted pro-inflammatory cytokines during HIV-1 infec-
tion are also known to alter the expression of drug efflux
transporters. Our previous work in rodent and human as-
trocytes suggests that gp120 can significantly downregulate
P-gp functional expression [5]. We have also observed
an increase in Mrp1 functional expression in response to
gp120 in primary cultures of rat astrocytes [3,12]. How-
ever, whether gp120 can modulate the expression of these
transporters in vivo in a similar manner is yet to be
characterized.
Several classes of antiretrovirals have been reported to
poorly permeate into the brain, whereas better permeable
antiretroviral drugs can be associated with adverse side ef-
fects including neurotoxicity [13]. Due to the complexities
associated with the treatment of brain HIV-1 infection
and HIV-associated chronic secretion of inflammatory
mediators, much interest has risen in identifying potential
adjuvant therapies that can be used along with antiretro-
viral drugs. For example, minocycline, a second generation
tetracycline derivative, has been considered as a potential
candidate due to its versatile role in neuroprotection in
different brain disease models [14,15]. Chloroquine, an
antimalarial drug and simvastatin, a 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitor, have also dem-
onstrated an anti-inflammatory and anti-HIV effect at
non-toxic concentrations in vitro or in vivo [16-19].
Furthermore, minocycline, chloroquine and simvastatin
can inhibit mitogen-activated protein kinase (MAPK)
signaling pathways (extracellular signal-related kinase
1/2 (ERK1/2), c-Jun N-terminal kinases (JNKs) and P38
kinases (P38Ks)) involved in generating inflammatory
responses [20]. In a clinical trial minocycline treatment
was found to be unsuccessful in improving the neuro-
cognitive outcome in patients with cognitive impairment
[21]. On the contrary, in a simian immunodeficiency virus
(SIV) model early administration of minocycline was re-
ported to be effective against striatal dopaminergic system
dysfunction, suggesting that timely treatment initiation
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these observations, we propose that early administration
of these anti-inflammatory compounds may have the po-
tential to reverse HIV-associated inflammatory response.
The objective of the present work was to implement
an in vivo model of HIV-associated inflammation by in-
tracerebroventricular (ICV) administration of viral coat
protein gp120 and to investigate the regulation of drug
transporters, tight junction proteins, signaling pathways
and the potential anti-inflammatory effects of chloro-
quine, minocycline and simvastatin.
Materials and methods
Materials
HIV-1ADA gp120 full-length protein (subtype B; R5-tropic)
and maraviroc were obtained from Immunodiagnostic Inc
(Woburn, Massachusetts, United States) and the National
Institutes of Health AIDS Research and Reference Reagent
program (Bethesda, Maryland, United States), respectively.
ERK1/2 inhibitor U0126 and simvastatin were purchased
from Cell Signaling (Whitby, Ontario, Canada) and Toronto
Research Chemicals (Toronto, Ontario, Canada), respect-
ively. Chloroquine, minocycline, JNK inhibitor SP600125,
murine monoclonal AC-40 antibody against actin, rabbit
polyclonal antibody against glial fibrillary acidic protein
(GFAP) and horseradish peroxidase (HRP) conjugated sec-
ondary antibodies (anti-mouse, anti-rabbit and anti-rat)
were obtained from Sigma-Aldrich (Oakville, Ontario,
Canada). Alexa fluor 488 donkey anti-rabbit, anti-occludin,
anti-zo1 and anti-claudin5 antibody, TRIzol™, DNAse I
and Prolong gold anti-fade reagent with 4',6-diamidino-2-
phenylindole (DAPI) were purchased from Invitrogen
(Carlsbad, California, United States). Tissue-Tek cryo-
optimum cutting temperature (OCT) formulation was
purchased from Thermo Fisher Scientific (Waltham,
Massachusetts, United States). ERK1/2, phospho-ERK1/2,
JNK, phospho-JNK, P38K and phospho-P38K antibodies
were obtained from Cell Signaling (Whitby, Ontario,
Canada). Murine monoclonal C219 antibody against P-
gp, rat monoclonal MRP1 antibody and anti-BCRP (rat
monoclonal) antibody were purchased from ID labs
(London, Ontario, Canada), Kamiya Biomedical Com-
pany (Seattle, Washington, United States) and Abcam
Inc (Boston, Massachusetts, United States), respectively.
Enzyme linked immunoabsorbant assay (ELISA) kits were
obtained from R&D Systems (Minneapolis, Minnesota,
United States). Guide cannula, dummy cannula, screws
and dental cement for stereotaxic surgery were purchased
from HRS Scientific (Montreal, Quebec, Canada). High
capacity reverse transcriptase cDNA synthesis kit and
SYBR Green Fastmix were obtained from Applied Biosys-
tems (Foster City, California, United States) and Quanta
Biosciences Inc (Gaithersburg, Maryland, United States),
respectively.Animals
This study was approved by the University of Toronto
Animal Care Committee, Toronto, Ontario, Canada.
Adult Wistar male rats (weighing approximately 250
grams; 12 weeks of age) were purchased from Charles
River Laboratories (St. Constant, Quebec, Canada). Ani-
mals were housed with rodent chow and water ad libi-
tum on a 12 hour light-dark cycle. All procedures were
carried out in accordance with the guidelines of University
of Toronto Animal Care Committee and the Canadian
Council on Animal Care. The rats were randomly assigned
to nine different groups: (1) wild-type (no surgery), (2)
control (saline), (3) heat-inactivated gp120, (4) gp120, (5)
maraviroc + gp120, (6) chloroquine + gp120, (7) minocy-
cline + gp120, (8) simvastatin + gp120, (8) JNK inhibitor
SP600125 + gp120, and (9) ERK1/2 inhibitor U0126 +
gp120.
Animal surgery and ICV administration of gp120/
maraviroc/signaling pathway inhibitors
Animals were anaesthetized with isoflurane (2 to 3%). The
implantation of the guide cannula was performed according
to previously published protocols using the following
stereotaxic coordinates: 1 mm posterior to bregma, 1.5 mm
lateral from midline and 3.5 mm ventral from the surface
of the skull according to the Atlas of Paxinos and Watson
[22,23]. Ketoprofen (5 mg/kg) was administered subcutane-
ously during surgery for pain relief. Animals were allowed
to recover for seven days after surgery. Following recovery,
animals were administered a single dose of (100 ng or
300 ng or 500 ng) gp120ADA (R5-tropic; clade B) daily for
seven consecutive days ICV using a 5 μl Hamilton syringe.
gp120 was diluted into a sterile normal saline solution and
administered in a volume of 2 μl (such as 250 ng/μl) over
2 minute period. Control animals received equal amount of
saline. Heat-inactivated gp120 was also administered for
seven days as an additional control group. Maraviroc, a
selective CCR5 antagonist, was administered 30 minutes
prior to gp120 administration for seven days (4 μl/4 mi-
nutes; 250 ng/μl in 1% dimethyl sulfoxide (DMSO)). ERK1/
2 inhibitor U0126 (7 μg) and JNK inhibitor SP600125
(10 μg) were administered ICV prior to gp120 administra-
tion at the same rate (4 μl/4 minutes; dissolved in 1.5%
DMSO).
Intraperitoneal administration of minocycline,
chloroquine and simvastatin
Minocycline (50 mg/kg loading dose followed by 25 mg/
kg/day) or chloroquine (25 mg/kg/day) or simvastatin
(1 mg/kg) was administered daily for seven consecutive
days by a single intraperitoneal injection 30 minutes prior
to ICV gp120 administration. Minocycline and chloro-
quine were dissolved in sterile water and simvastatin was
dissolved in a 1% DMSO solution.
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fluid collection
Twenty four hours after the last injection, animals were
anaesthetized and CSF samples were collected by cis-
terna magna puncture according to previously published
protocol [24]. Subsequently, anaesthetized animals were
perfused through the left ventricle of the heart with
200 ml of saline solution and whole rat brains were har-
vested. For real-time qPCR and immunoblot analysis,
brains were dissected on ice to isolate frontal cortex,
hippocampus and striatum from both hemispheres. Sam-
ples were flash frozen in liquid nitrogen and kept at -80°C.
Capillaries were also isolated from saline and gp120-
injected rat brains following previously published protocol
[25]. For immunohistochemical analysis, saline perfusion
was followed by 180 ml of paraformaldehyde (4%) dis-
solved in phosphate-buffered saline (PBS) perfusion before
collecting whole brains. These samples were stored in
50 ml paraformaldehyde (4%) at 4°C.
Quantitative real-time PCR
Real-time qPCR was applied to determine the gene ex-
pression of inflammatory markers according to previously
described protocols followed by our laboratory [26].
Briefly, total RNA was extracted from brain regions using
TRIzol™ (Invitrogen, Carlsbad, California, United States)
reagent and the high capacity cDNA reverse transcriptase
kit (Applied Biosystems, Foster City, California, United
States) was used to synthesize first-strand cDNA. Prix-
mer pairs for the rat interleukin-1β (IL-1β) gene (5-
CTCAACTGTGAAATAGCAGCTTTC–3 and 5 GGA
CAGCCCAAGTCAAGG–3), rat tumor necrosis factor-α
(TNF-α) (5-TCTTCTCATTCCTGCTCGTG–3 and 5-
GATGAGAGGGAGCCCATTT–3), rat inducible nitric
oxide synthase (iNOS) (5-CCAAGGTGACCTGAAA-
GAGG–3 and 5 TTGATGCTTGTGACTCTTAGGG–3),
rat IL-6 (5-CTTCACAAGTCGGAGGCTTAAT–3 and 5-
ACAGTGCATCATCGCTGTTC–3) and the rat Cyclo-
philin B gene (housekeeping gene; 5-GGAGATGGCAC
AGGAGGAA-3 and 5-GCCCGTAGTGCTTCAGCTT-3)
were designed using Primer Express 3 software (Applied
Biosystems, Foster City, California, United States))
and were validated for specificity and efficacy using
lipopolysaccharide-treated rat astrocyte samples. Quan-
titative PCR was performed using SYBR Green Master
Mix (Quanta Biosciences Inc, Gaithersburg, Maryland,
United States) using an Eppendorf Real-time PCR Sys-
tem (Eppendorf Canada, Mississauga, Ontario, Canada)
at 25°C for 10 minutes, followed by 37°C for 120 mi-
nutes, and 85°C for 5 minutes. A relative quantification
was performed by comparing the threshold cycle
values of samples with serially diluted standards. Ex-
pression levels were normalized to housekeeping gene
Cyclophilin B.Enzyme linked immunoabsorbant assay (ELISA)
Commercially available colorimetric sandwich ELISA
kits for rat IL-1β and TNF-α were used to detect the
secretion of these cytokines in CSF in the presence or
absence of maraviroc, chloroquine, minocycline and
simvastatin. CSF collected from control (no surgery)
and ICV heat-inactivated gp120-administered animals
was analyzed as an additional control group. The assays
were performed according to the manufacturer’s instruc-
tion with slight modifications as previously described in
our laboratory. Standard curves were generated using ap-
propriate rat cytokines and absorbance read at 450 nm
was converted to pg/ml. We confirmed the minimal de-
tection level to be 2.5 pg/ml and 1.5 pg/ml for IL-1β and
TNF-α, respectively.
Immunoblot analysis
Immunoblotting was performed as described previously in
our laboratory [5]. Tissue and capillary homogenates were
prepared using a lysis buffer (1% (v/v) NP-40 in 20 mM
tris, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid
(EDTA) at pH 7.5 containing 1 mM phenylmethanesulfo-
nyl fluoride and 0.1% (v/v) protease inhibitor cocktail).
Tissues were sonicated for 10 seconds and centrifuged at
20,000 g for 10 minutes at 4°C to remove cellular debris.
Protein concentrations of tissue or capillary homogenates
were determined using Bradford’s protein assay (Bio-rad
laboratories, California, United States). Total protein (1 μg,
5 μg to 50 μg) were separated on 7 to 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto a polyvinylidene difluoride mem-
brane. After blocking with 5% skim milk for one hour, the
membrane was probed for protein of interest with primary
antibody (anti-P-gp (C219), 1:500; Mrp1, 1:500; Bcrp,
1:500; β-actin, 1:2000; ZO-1, 1:500; occludin, 1:500;
claudin5, 1:250; GFAP, 1:1000; iNOS, 1:500; ERK1/
2,1:250; phospho-ERK1/2, 1:100; JNK, 1:250; phospho-
JNK, 1:100; P38K, 1:250; phospho-P38K, 1:100). β-Actin
was used as loading control. HRP-conjugated secondary
antibody was added after washes in tris-buffered saline
with Tween. After further washing, bands were de-
tected using enhanced chemiluminescent reagent (Thermo
Fischer Scientific, Ontario, Canada). Densitometric analysis
was performed in AlphaDigiDoc RT2 software (Alpha
Innotech, San Leandro, California, United States) to quan-
tify relative protein expression. The graphs represent
relative density of the bands of interest normalized to
corresponding β-actin.
Immunohistochemistry
Immunohistochemistry was performed according to previ-
ously published protocol [27]. Briefly, paraformaldehyde-
fixed samples were transferred to a 30% sucrose solution
and kept overnight at 4°C before mounting with OCT
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pared at Murine Imaging and Histology Facility (Faculty
of Pharmacy, University of Toronto, Toronto, Ontario,
Canada). Sections were incubated in blocking buffer
(5% goat serum and 0.2% Triton X-100 in 0.1 M PBS)
for one hour followed by overnight incubation with pri-
mary antibody at 4°C (Anti-GFAP, 1:200). Following in-
cubation, sections were washed thoroughly in PBS and
incubated for two hours in Alexa-Fluor conjugated sec-
ondary antibody (1:200). After further washing, cover-
slips were mounted onto the specimen using a prolong
gold anti-fade mounting medium with DAPI. Specimens
were examined using a Nikon E1000 fluorescent micro-
scope (Nikon Corp., Mississauga, Canada). Images were
captured using the software SimplePCI (Compix, Inc., Im-
aging Systems, Sewickley, Pennsylvania, United States).
Data analysis
Student’s t-test was used to determine statistical signifi-
cance between two groups. Multiple comparisons were
performed using analysis of variance (ANOVA) and
Bonferroni’s post-hoc analysis. A P value less than 0.05
was considered to be statistically significant. Data were
analyzed using GraphPad Prism software (San Diego,
California, United States). Samples collected from three
to twelve animals per group were used.
Results
gp120-mediated inflammatory response in the brain
Previous studies have demonstrated that ICV or region-
specific administration of different strains of gp120 from
100 ng to 500 ng into rodents can induce an inflamma-
tory response [28,29]. In our hands, administration of
100 ng to 300 ng HIV-1 gp120ADA daily for seven days
in adult male Wistar rats did not induce a significant in-
flammatory response in brain tissue (data not shown).
Therefore, a dose of 500 ng was chosen. At this dose, we
observed a significant upregulation of IL-1β, iNOS and
TNF-α in different brain regions. Compared to saline-
administered animals, in gp120 (500 ng)-injected rats,
transcripts of IL-1β, iNOS and TNF-α were significantly
elevated in the frontal cortex, whereas, elevated IL-1β
and iNOS mRNA were observed in the hippocampus
and striatum (Figure 1A-C). No significant change was
observed in IL-6 transcript levels (data not shown).
Heat-inactivated gp120 did not induce any changes in
inflammatory markers and remained comparable to saline
treatment (Figure 1A-C). ANOVA analysis performed for
different regions in Figure 1 did not show a significant dif-
ference of IL-1β, iNOS and TNF-α transcripts between
wild-type animals (no surgery) and saline-treated animals
(Figure 1A-C).
Our previous work in vitro suggested that R5-tropic
gp120 could interact with CCR5 chemokine receptorsresulting in pro-inflammatory cytokine secretion [5]. In
order to demonstrate that the inflammatory response
observed in gp120-administered animals is mediated by
the specific interaction of gp120 with CCR5 chemokine
receptor in vivo, we administered maraviroc, a CCR5 an-
tagonist ICV prior to gp120 administration in rodents.
Administration of maraviroc (1 μg) resulted in a down-
regulation of IL-1β, iNOS and TNF-α transcript levels in
different brain regions when compared to only gp120-
treated animals (Figure 1A-C).
At the protein level, a significant increase in TNF-α
and IL-1β was also detected in CSF samples collected
from gp120-administered animals (Figure 2A and B).
Consistent with the qPCR data, maraviroc treatment at-
tenuated the gp120-mediated secretion of cytokines.
Also, heat-inactivated gp120-mediated secretion of IL-1β
and TNF-α was found to not be significantly different
from saline-treated animals (Figure 2A and B).
gp120-mediated activation of astrocytes
ICV administration of gp120 has previously been shown to
result in astrocyte activation in vivo as demonstrated by an
increase in GFAP expression, a cellular marker for astro-
cyte [29]. Therefore, in our model we investigated expres-
sion of GFAP using immunohistochemistry (Figure 3A). In
gp120-administered animals, we observed an increase in
GFAP staining in the hippocampus. This was further con-
firmed by immunoblotting analysis (Figure 3B).
Effect of gp120 on tight junction proteins and drug efflux
transporters in brain capillaries
Previous studies have reported a breakdown of the blood-
brain barrier in models of brain HIV-1 infection in vitro
and in vivo [11]. In order to determine the integrity of the
blood-brain barrier in our in vivo model, we examined the
expression of tight junction proteins (occludin, ZO-1,
claudin5) as well as drug efflux transporters (P-gp, Mrp1
and Bcrp) in brain capillaries isolated from gp120-treated
animals. We did not observe any significant changes in
ZO-1, occludin, claudin5, P-gp, Mrp1 and Bcrp protein
expression in brain capillaries isolated from saline or
gp120-administered rats (data not shown).
Effect of gp120 on drug efflux transporter expression in
brain regions
We have previously shown in vitro that gp120 exposure
can significantly decrease P-gp protein expression and
increase Mrp1 protein expression in primary cultures of
rat astrocytes and/or human fetal astrocytes. However,
it was unknown if gp120 could alter the expression of
these transporters in vivo. Applying immunoblot ana-
lysis, we detected significant changes in P-gp, Mrp1 and
Bcrp protein expression in different brain regions of
gp120-treated animals (Figure 4). gp120 administration
Figure 1 Effect of gp120 on the mRNA levels of (A) IL-1β, (B) iNOS
and (C) TNF-α in different brain regions of ICV-administered
gp120 (500 ng) rats along with a CCR5 antagonist, maraviroc
(MVC). Wild-type (no surgery), control (saline) and heat-inactivated (HI)
gp120-injected animals were also analyzed. Results are expressed as
mean ± SEM (n = 10 for saline and gp120 groups; n = 3 for wild-type,
HI gp120 and maraviroc-treated groups). Asterisks represent data points
significantly different from saline-administered animals (***P <0.001;
**P <0.01; *P <0.05). (gp120 = glycoprotein120; IL-1β = interleukin-1β;
iNOS = inducible nitric oxide synthase; TNFα= tumor necrosis factor-α;
ICV = intracerebroventricular; MVC =Maraviroc; HI = heat inactivated).
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sion in the frontal cortex and hippocampus (40 and
30%, respectively) (Figure 4A and B). In the striatum of
gp120-treated animals, we did not detect any significant
changes in P-gp protein expression compared to saline-
administered animals (Figure 4C). A significant upregula-
tion of Mrp1 was observed in hippocampus and striatum
(67 and 68%, respectively) (Figure 4B and C), whereas,
no significant change was detected in the frontal cortex
(Figure 4A). Bcrp, another drug efflux transporter, was
found to be upregulated in the frontal cortex (118%
compared to saline) (Figure 4A) but not in the hippo-
campus and striatum (Figure 4B and C).
Anti-inflammatory effects of chloroquine, minocycline
and simvastatin
Animals were administered gp120 (500 ng) ICV with or
without prior intraperitoneal administration of minocycline
or chloroquine or simvastatin in order to assess their po-
tential anti-inflammatory effect. Administration of minocy-
cline or chloroquine partially or completely suppressed the
gp120-induced upregulation of the inflammatory markers
examined (Figure 5). In particular, administration of
minocycline or chloroquine completely attenuated gp120-
mediated upregulation of IL-1β and iNOS transcripts in
all three brain regions (Figure 5A-C).
Minocycline was also effective in suppressing TNF-α
transcripts in brain tissues and both TNF-α and IL-1β se-
cretion in the CSF of gp120-administered animals, whereas
chloroquine only attenuated IL-1β secretion (Figure 6A
and B). Simvastatin attenuated both IL-1β and iNOS tran-
scripts in the hippocampus and striatum (Figure 5A
and B), but only suppressed iNOS in the frontal cortex
(Figure 5B). At the protein level, however, simvastatin
could not significantly suppress gp120-mediated IL-1β
and TNF-α secretion in the CSF (Figure 6A and B).
gp120-mediated activation of signaling pathways
The three main subfamilies of the MAPK pathway (ERK1/
2, JNK and P38K) are known to be actively involved in
regulating cytokine secretion [30]. Therefore, we inves-
tigated the activation of ERK1/2, JNK and P38K in dif-
ferent brain regions of gp120-administered animals. In
Figure 2 ELISA analysis of (A) IL-1β and (B) TNF-α secretion in
the CSF of gp120 (500 ng) administered rats in the presence of
maraviroc (MVC). CSF collected from saline- and heat-injected
animals were used as control. Results are expressed as mean ± SEM
(n = 10 for saline and gp120 groups; n ≥3 for wild-type, HI gp120
and maraviroc-treated groups). Asterisks represent data points
significantly different from saline-administered animals (***P <0.001;
**P <0.01). (ELISA = Enzyme linked immunoabsorbant assay; IL-1β =
interleukin-1β; TNFα = tumor necrosis factor-α; CSF = cerebrospinal
fluid; gp120 = glycoprotein120; MVC =Maraviroc; HI = heat inactivated).
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2 and JNKs (Figure 7A), however, we did not detect sig-
nificant changes in ERK1/2, JNK or P38K phosphorylation
in the frontal cortex and striatum (data not shown). Ad-
ministration of minocycline and simvastatin significantly
reduced ERK1/2 phosphorylation, whereas the effect of
chloroquine was not found to be significant (Figure 7B).
gp120-mediated JNK phosphorylation was found to not beaffected despite treatment with anti-inflammatory com-
pounds (data not shown). However, in our in vitro model
of primary cultures of rat astrocytes triggered with gp120,
we detected attenuation of both ERK1/2 and JNKs in the
presence of minocycline, chloroquine and simvastatin
(data not shown). In order to further demonstrate that the
gp120-mediated activation of these pathways can be atten-
uated in our model, inhibitors of ERK1/2 (U0126) and
JNK (SP600125) pathways were administered ICV daily
prior to gp120 administration and we confirmed signifi-
cant inhibition of ERK1/2 and JNK phosphorylation, re-
spectively (Figure 7C and D).
Discussion
A number of pro-inflammatory cytokines (TNF-α, IL-1β,
IL-6, IFN-γ) and oxidative stress markers (such as nitric
oxide) are known to be elevated during brain HIV-1 in-
fection. HIV-1 coat protein gp120 has previously been
shown to generate an inflammatory response and oxida-
tive stress both in vitro and in vivo [3,5,23]. This viral
protein is shed during HIV-1 replication and circulating
levels of gp120 have been detected in plasma and in the
CSF [31-35]. Our laboratory has extensively investigated
gp120-mediated release of pro-inflammatory cytokines
and oxidative stress in primary cultures of rodent astro-
cytes as well as in human fetal astrocytes exposed to
viral isolates in vitro [3,5,6]. In this study, we imple-
mented an in vivo model of brain inflammation by ICV
administration of gp120. In different models, doses of
gp120 ranging from 100 to 500 ng (administered intrace-
rebrally) have been shown to induce an inflammatory re-
sponse [29]. In our model, ICV administration of 500 ng
of HIV-1 gp120ADA resulted in a significant upregulation
of different inflammatory markers in the frontal cortex,
hippocampus and striatum. Heat-denatured gp120 failed
to generate an inflammatory response, suggesting that a
native gp120 structure is necessary to interact with che-
mokine receptors to induce an inflammatory response.
We observed upregulation of IL-1β, iNOS and TNF-α in
the frontal cortex of gp120-administered animals. In the
hippocampus and striatum, IL-1β and iNOS transcripts
were found to be elevated due to gp120 treatment. These
markers are known to be upregulated during HIV-1 infec-
tion [4,28]. We also observed enhanced secretion of cyto-
kines IL-1β and TNF-α in the CSF. Previously, increased
GFAP expression has been observed in HIV-1 infected
brain [36]. In our model, we observed a significant in-
crease in GFAP expression in the hippocampus, indicating
activation of astrocytes in this region.
Interaction of gp120 and chemokine receptors has pre-
viously been reported in vitro [5,6]. Previous work from
our laboratory has detected expression of CCR5 in both
human and rat primary culture of astrocytes. Using neu-
tralizing antibodies against CCR5 and CXCR4 receptors,
Figure 3 GFAP expression in the hippocampus of ICV-administered gp120 rats. (A) Immunohistochemical, (B) immunoblotting (upper
panel) and densitometric analysis (lower panel) of GFAP in the hippocampus of ICV-administered gp120 rats are compared to saline-treated
animals. A representative blot is shown. Results are expressed as mean ± SEM. For immunoblotting, samples obtained from five different animals
were used per group. Asterisk represents a data point significantly different from saline-administered animals (*P <0.05). (GFAP = glial fibrillary
acidic protein; ICV = intracerebroventricular; gp120 = glycoprotein120).
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with CCR5 chemokine receptors and result in pro-
inflammatory cytokines (IL-1β, IL-6 and TNFα) secre-
tion in vitro [5,6]. Maraviroc is a potent and specific
inhibitor of CCR5 that is clinically used to treat HIV-1
infection. Consistent with our in vitro findings, mara-
viroc attenuated the gp120-mediated increase in IL-1β,
iNOS and TNF-α in our in vivo model suggesting that the
mechanism of gp120-associated inflammation is CCR5-
receptor dependent. These findings provide evidence of
in vivo interaction of gp120 with CCR5 receptor and
emphasize the critical role of this interaction in generating
a brain inflammatory response.Downregulation of tight junction proteins (such as
occludin, ZO-1, claudin5) has been implicated in the
pathogenesis of brain HIV-1 infection [11]. A compro-
mised blood-brain barrier can facilitate entry of HIV-1
from the periphery, and can ultimately increase the spread
of the virus in brain parenchymal cellular compartments.
Although in vitro and in vivo studies have demonstrated
that HIV-1 proteins (like gp120 and tat) can downregulate
tight junction proteins expressed in brain microvessel
endothelial cells, [7,37], we did not observe any significant
change in tight junction proteins expression in our model.
This lack of effect may be due to the dose, duration and/
or strain of the gp120 treatment we used. Persidsky et al.
Figure 4 Immunoblot (upper panel) and densitometric analysis (lower panel) of drug efflux transporters (P-gp, Mrp1 and Bcrp) in
(A) frontal cortex, (B) hippocampus and (C) striatum of ICV-administered gp120 rats. Transporter over-expressing cell lines were used as
positive controls. Representative blots are shown. Results are expressed as mean ± SEM. Samples obtained from six different animals were used
per group. Asterisks represent data points significantly different from saline-administered animals (**P <0.01; * P <0.05). (P-gp = P-glycoprotein;
Mrp1 =multidrug resistance protein 1; Bcrp = breast cancer resistance protein; ICV = intracerebroventricular; gp120 = glycoprotein120).
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associated with Rho activation in brain microvessel endo-
thelial cells and this activation was mediated by monocyte
migration across these cells [38]. Ricardo-Dukelow et al.
demonstrated that HIV-1 infected macrophages upregu-
late a number of proteins in brain microvessel endothelial
cells that may lead to blood-brain barrier disruption [39].
Therefore, lack of immune cell infiltration could be an-
other potential reason for lack of change in tight junction
protein expressions in our model. We also did not detectFigure 5 Effect of gp120 on the mRNA levels of (A) IL-1β, (B) iNOS an
rats receiving simultaneous intraperitoneal injection of chloroquine o
control. Results are expressed as mean ± SEM. Samples obtained from at le
points significantly different from saline-administered animals (***P <0.001;
different from gp120 treatment (♦♦♦P <0.001; ♦♦P <0.01). (gp120 = glycopr
TNFα = tumor necrosis factor-α; ICV = intracerebroventricular; CQ = chloroquany significant changes in transporter protein expression
in the capillaries.
Tight junction proteins form a physiological barrier at
the brain capillary level, whereas a biochemical barrier also
exists both at the blood-brain barrier level and in brain
parenchyma. This biochemical barrier primarily consists
in the expression of drug efflux transporters and several
metabolizing enzymes that restrict the bioavailability of a
number of antiretroviral drugs into the brain. Modulation
of these transporters by pathological stimuli has beend (C) TNF-α in different brain regions of ICV-administered gp120
r minocycline or simvastatin. Saline-injected animals were used as
ast 10 different animals were used per group. Asterisks represent data
**P <0.01; *P <0.05). Diamonds represent data points significantly
otein120; IL-1β = interleukin-1β; iNOS = inducible nitric oxide synthase;
ine; Mino =minocycline; Sim = simvastatin).
Figure 6 ELISA analysis of (A) IL-1β and (B) TNF-α secretion in
the CSF of gp120 (500 ng) administered rats receiving
simultaneous intraperitoneal injection of chloroquine or
minocycline or simvastatin. CSF collected from saline-injected
animals was used as a control. Results are expressed as mean ± SEM.
Samples obtained from at least 10 different animals were used per
group. Asterisks represent data points significantly different from
saline-administered animals (***P <0.001; **P <0.01). Diamonds
represent data points significantly different from gp120 treatment
(♦♦♦P <0.001). (ELISA = Enzyme linked immunoabsorbant assay;
IL-1β= interleukin 1β; TNFα= tumor necrosis factorα; CSF = cerebrospinal
fluid; gp120 = glycoprotein120; CQ = chloroquine; Mino =minocycline;
Sim = simvastatin).
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at the gene and protein level has been reported in brain
autopsy samples from patients with HIVE as well as inbrain tissue collected from a severe combined immunodefi-
ciency mice model of HIVE [11]. In vitro, HIV-1 viral iso-
lates or gp120-mediated downregulation of P-gp has also
been reported by our laboratory in both rodent and human
astrocytes [5,6]. Consistent with these data, in our in vivo
model, we observed downregulation of this transport pro-
tein expression in the frontal cortex and hippocampus fur-
ther confirming that gp120 has a down-regulatory effect on
P-gp functional expression in brain parenchyma.
Altered functional expression of Mrp1 has also been
reported in the context of HIV-1. Hayashi et al. reported
tat-induced upregulation of Mrp1, both at the gene and
protein level in cultured astrocytes [40]. In primary cul-
tures of rat astrocytes triggered with gp120 or TNF-α, we
also detected an increase in Mrp1 functional expression
[3,12]. In the present study, a significant upregulation of
Mrp1 in the hippocampus and striatum was detected, fur-
ther suggesting that gp120 exerts an up-regulatory effect
on Mrp1 protein expression in vivo. In our hands, Bcrp
was also found to be upregulated in the frontal cortex of
gp120-treated animals. In contrast, IL-1β and TNF-α-
mediated downregulation of Abcg2 has previously been re-
ported in porcine brain microvessel endothelial cells [42].
These results indicate that, similar to other drug efflux
transporters, Bcrp is susceptible to modulation by inflam-
matory cytokines. However, cytokine-mediated regulation
of this transporter could be species and/or cell specific.
Our in vivo data are consistent with previous in vitro find-
ings in glial cells where exposure to gp120 resulted in a
significant production of pro-inflammatory cytokines along
with a downregulation of P-gp expression and an upre-
gulation of Mrp1 expression [3,5,6]. Together, these obser-
vations provide evidence that regulation of drug efflux
transporters is highly complex during HIV-associated brain
inflammation. Since a number of antiretroviral drugs are
known substrates for these transporters, changes in the ex-
pression of these transporters in brain parenchyma may re-
sult in an altered distribution of antiretroviral drugs at
cellular targets of HIV-1 infection.
To date, only a few studies have reported on the neu-
roprotective and anti-inflammatory potential of different
compounds (such as minocycline, curcumin, neuroster-
oids) in attenuating a HIV-associated inflammatory re-
sponse [15,43,44]. The limitations of currently used
antiretroviral drugs include lack of anti-inflammatory
properties, poor brain permeability and neurotoxicity
associated with better permeable drugs. Since neuro-
logical disorders are becoming more prevalent in HIV-1
infected patients and inflammation is a common im-
mune response, identifying therapeutic compounds that
can effectively permeate the blood-brain barrier, exhibit
anti-inflammatory properties, and are well tolerated
may provide an additional option in preventing and/
or treating HIV-associated neurological disorders. For
Figure 7 Protein (upper panel) and densitometric analysis (lower panel) of (A) ERK1/2 and phospho-ERK1/2; JNK and phospho-JNK;
P38K and phospho-P38K, (B) ERK1/2 and phospho-ERK1/2 in the presence of chloroquine, minocycline and simvastatin, (C) ERK1/2 and
phospho-ERK1/2 in the presence of ERK1/2 inhibitor U0126; (D) JNK and phospho-JNK in the presence of SP600125 in the hippocampal
tissue of gp120-administered rats. Representative blots are shown. Tissue collected from saline-administered animals was used as control.
Results are expressed as mean ± SEM. Samples obtained from three to six different animals per group were used. Asterisks represent data points
significantly different from saline-administered animals (***P <0.001; *P <0.05). Diamonds represent data points significantly different from
gp120-treatment (♦P <0.05). (ERK1/2 = extracellular signal-related kinase 1/2; p-ERK1/2 = phospho- ERK1/2; JNKs = c-Jun N-terminal kinases;
p-JNKs = phospho-JNKs; P38Ks = P38 kinases; p-P38Ks = phosphor-p38Ks; gp120 = glycoprotein120).
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of neurosteroid, dehydroepiandrosterone sulfate, in pre-
venting inflammation and neurodegeneration as well
as behavioral deficits in a feline immunodeficiency virus
model [44]. Minocycline, a second generation tetracycline
derivative, has been reported by many to have anti-
inflammatory properties both in vitro and in vivo [15,45].
In an amyloid-beta injected rat model, minocycline has
shown to successfully reverse the activation of glial cells
[45]. In our study, minocycline also effectively inhibited
gp120-mediated upregulation of different inflammatory
markers in the frontal cortex, hippocampus and striatum
and further prevented secretion of cytokines in the CSF.
Recently, minocycline has been tested in a clinical trial
in HIV-infected patients with cognitive impairment. Al-
though this study reported that minocycline treatment
was unsuccessful in improving neurocognitive function in
patients with cognitive impairment, [21] it is still incon-
clusive if administration of the drug at earlier stages of the
infection could have a better clinical outcome. Since min-
ocycline has been reported to have a safe profile when
administered with antiretroviral drugs in HIV-infected in-
dividuals, it will be important to assess if early administra-
tion of antiretroviral drugs along with minocycline has any
beneficial effects against HIV-associated neurocognitive
disorders. Several clinical studies indicate earlier adminis-
tration of antiretroviral drugs can decrease the incidenceof neurological disorders [46]. In a SIV model, early ad-
ministration of minocycline was reported to be effective
against striatal dopaminergic system dysfunction, suggest-
ing that timely treatment initiation may have an effect on
minocycline efficacy [15]. Since antiretroviral drugs (with
the exception of maraviroc) do not have anti-inflammatory
properties, a combination therapy including antiretroviral
and anti-inflammatory compounds may prevent the devel-
opment of HIV-associated cognitive deficits.
We also tested chloroquine, an antimalarial drug which
exhibits anti-inflammatory and anti-HIV effects in vitro
and in vivo. For example, chloroquine administration has
been reported to reduce T-cell activation in chronic HIV-
infected patients [47]. In a rodent model, chloroquine pre-
vented a bacterial toxin-induced intracerebral toxicity [17].
In our gp120-administered model, chloroquine was able to
suppress IL-1β and iNOS mRNA levels in the frontal cor-
tex, hippocampus and striatum. Chloroquine was also ef-
fective in reversing gp120-mediated IL-1β release in the
CSF. However, chloroquine was not able to inhibit gp120-
mediated release of TNF-α. Clinical trials are necessary to
determine whether chloroquine could be beneficial in re-
ducing HIV-associated cognitive impairments, particularly
in populations where malaria is also prevalent. Simvastatin,
an HMG-CoA reductase inhibitor, is another compound
that has demonstrated anti-inflammatory properties and
neuroprotective effects [16,48]. In a study by Andras et al.,
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upregulation of inflammatory genes in human brain
microvessel endothelial cells [16]. In another study, this
drug attenuated oxidative stress and inflammation and
also restored short-term and long-term memory in a
transgenic mice model of Alzheimer’s disease [48]. In our
study, simvastatin was able to suppress IL-1β and iNOS in
the hippocampus and striatum, but had minimal effect on
IL-1β and TNF-α transcript levels in the frontal cortex.
Also, the 1 mg/kg dose of simvastatin was not able to at-
tenuate the secretion of cytokines in the CSF. In contrast
to several other statins, simvastatin is known to have good
permeability into the brain. However, in the periphery,
simvastatin is highly metabolized by cytochrome P450 en-
zymes which can result in adverse drug-drug interaction
with HIV-protease inhibitors making it a less ideal candi-
date for adjuvant therapy in HIV-infected individuals.
Anti-inflammatory properties of statins that are not sub-
strate of cytochrome p450 (rosuvastatin or pravastatin) or
less potent inhibitors of cytochrome p450 (atorvastatin)
should be considered in future studies.
Experimental data from various in vitro models suggest
the involvement of different signal transduction pathways
in the regulation of cytokine secretion and drug trans-
porters during HIV-associated inflammation [6,12,40]. Po-
tential anti-inflammatory compounds are also known to
target different signaling pathways to attenuate the inflam-
matory response. In particular, MAPKs are widely known
to be involved in various pathological processes associated
with HIV-1 infection (such as neurotoxicity, macrophage
activation, viral replication) [49]. Studies have further dem-
onstrated that inhibition of these kinases can downregulate
HIV-1 infection as well as decrease transcellular transport
of HIV-1 across blood-brain barrier in vitro [49-51]. There-
fore, we examined these pathways in our gp120-associated
brain inflammation model and observed activation of
ERK1/2 and JNKs in the hippocampus. The presence of
minocycline or simvastatin decreased the gp120-mediated
phosphorylation of ERK1/2 but not JNKs in the hippocam-
pus. Since a number of studies suggest that chloroquine,
simvastatin and minocycline can attenuate JNK activation
in vitro or in vivo, we speculate that the lack of effect of
these compounds on JNK phosphorylation could be time-
dependent and could not be delineated in our in vivo
model [20]. However, using specific inhibitors of ERK1/2
and JNK pathway, we were able to attenuate the gp120-
mediated activation of these two pathways in vivo.
In summary, using a gp120-induced brain inflammation
model in vivo, we have demonstrated that compounds
with anti-inflammatory properties have the potential to
prevent or reduce brain inflammation by interacting with
signaling pathways. In our model, we have also observed
altered expression of drug transporters due to gp120-
mediated brain inflammation in vivo. The expression ofABC transporters expressed at the blood–brain barrier, in
part, regulate the permeability of antiretroviral drugs into
the brain. In addition, drug transporters localized at brain
parenchymal cellular compartments also contribute to-
wards the drug disposition in central nervous system.
Alteration of these transporters due to HIV-associated
pathogenesis and/or antiretroviral therapy may change the
therapeutic outcome. Many different factors determine the
effectiveness of antiretroviral therapy in improving neuro-
cognitive impairment. We propose that identification of
compounds with anti-inflammatory properties will signifi-
cantly benefit patients with neurocognitive impairments.
Conclusions
The major findings from our work revealed that agents
such as minocycline, chloroquine and simvastatin which
are known to display anti-inflammatory properties, are
effective in reducing brain inflammation triggered by the
HIV-1 viral envelope protein, gp120 in an in vivo rodent
model. Furthermore, we demonstrated that this effect
is mediated, in part, through an interaction with the
MAPK signaling pathway. Future studies are needed to
determine the efficacy of the early administration of
antiretroviral drugs along with adjuvant therapy against
the progression of HIV-associated brain inflammation as
well as cognitive deficits.
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